THU-140-Characteristics of patients and effectiveness of chronic hepatitis C treatment during the initial 4 years of access to interferon-free therapy

Flisiak, Robert; Lorenc, Beata; Klapaczyński, Jakub; Janczewska, Ewa; Mazur, Włodzimierz; Zarębska-Michaluk, Dorota; Tudrujek, Magdalena; Tomasiewicz, Krzysztof; Dybowska, Dorota; Halota, Waldemar; Sitko, Marek; Orłowska, Iwona; Simon, Krzysztof; Czauż-Andrzejuk, Agnieszka; Belica-Wdowik, Teresa; Berak, Hanna; Jaroszewicz, Jerzy; Krygier, Rafał; Anna, Piekarska; Socha, Łukasz; Citko, Jolanta; Dobracka, Beata; Tronina, Olga; Deroń, Zbigniew; Laurans, Łukasz; Białkowska-Warzecha, Jolanta; Pawłowska, Matgorzata

doi:10.1016/s0618-8278(19)30415-3

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mortality of HCV-infected patients for the period prior to the interferon-free (IFN-free) era was assumed to be 3% on the basis of SP data for age category corresponding to the average age of patients treated for HCV in Poland at that time. Due to obvious demographic changes observed in the treated population (lower median age, significant reduction of cirrhotics) in subsequent years we used the mortality rate estimated in the EpiTer-2 database [14]. For forecasting tasks this parameter was assumed to be constant after the year 2018 (Table 1).…”

Section: Methodsmentioning

confidence: 99%

“…The number of annual antivirals treatments in the period 2009-2015 was estimated on the basis of data from the National Health Fund (NHF). For the years 2016-2018 it was calculated based on the contract value and unit cost of every type of treatment option, maintaining the ratio of different regimens administered to patients from the EpiTer-2 database [14]. Projected data on number of treated patients were used to forecast after 2019 (Table 1).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Perspectives of hepatitis C virus (HCV) elimination in Poland

Flisiak

Zarębska-Michaluk

2019

ceh

Self Cite

View full text Add to dashboard Cite

Aim of the studyAccording to the World Health Organization (WHO) strategy, elimination of hepatitis C virus (HCV) as a major public health threat by 2030 includes diagnosis and cure of 90% of those infected between 2015 and 2030. The aim of this study is to estimate the realistic possibility to achieve the WHO elimination targets in Poland.Material and methodsThe Polish population was established according to data from Statistics Poland for the year 2017. Treatment efficacy was estimated based on publications in time-frames depending on the availability of therapeutic options in Poland. The mortality of HCV-infected patients was assumed on the basis of Statistics Poland and the EpiTer-2 database The number of annual antiviral treatments was estimated based on data from the National Health Fund. Two scenarios were considered, without and with intervention dependent on the national screening program.ResultsThe current diagnosis rate in Poland was calculated as 31%. The scenario without intervention resulted in gradual reduction of annual treatments accompanied by a decrease in the number of infected patients in 2030 to 118 000 (0.31% of the current Polish population), which is only 38% compared with 2015 established as a baseline by WHO. Introduction of the HCV screening program, which includes 3 million people annually, would increase treatment uptake to 12 000 per year and reduce the number of HCV-infected persons in Poland by 90%.ConclusionsThe urgent implementation of the national screening program for HCV in Poland is essential to achieve the WHO goal by 2030. The screening strategy should include up to 3 million persons annually to achieve treatment uptake of 12 thousand patients per year.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%